Journal of Clinical Oncology, Vol 10, 706-717, Copyright © 1992 by American Society of Clinical Oncology
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer [published erratum appears in J Clin Oncol 1992 Sep;10(9):1505]
DS Alberts, S Green, EV Hannigan, R O'Toole, D Stock-Novack, P Anderson, EA Surwit, VK Malvlya, WA Nahhas and CJ Jolles
University of Arizona Cancer Center, Tucson.
PURPOSE: To compare cisplatin-cyclophosphamide versus carboplatin-
cyclophosphamide as primary chemotherapy for stage III (suboptimal) and
stage IV ovarian cancer. PATIENTS AND METHODS: Three hundred forty-two
patients were randomly assigned to treatment with six courses of
intravenous (i.v.) cisplatin 100 mg/m2 plus i.v. cyclophosphamide 600
mg/m2, or i.v. carboplatin 300 mg/m2 plus i.v. cyclophosphamide 600 mg/m2.
RESULTS: The estimated median survivals were 17.4 and 20.0 months for the
cisplatin and carboplatin study arms, respectively. The null hypothesis of
a 30% survival superiority with the cisplatin arm was rejected at the P =
.02 level. Clinical response rates were 52% for the cisplatin arm and 61%
for the carboplatin arm. Pathologic complete response rates were similar
for both study arms. There was less thrombocytopenia on the cisplatin arm
(P less than .001); however, there was less nausea and emesis (P less than
or equal to .001 for courses 1 to 5), renal toxicity (P less than .001),
anemia (P = .01), hearing loss (P less than .001), tinnitus (P = .01),
neuromuscular toxicities (P = .001), and alopecia (P less than .001) on the
carboplatin arm. CONCLUSION: Carboplatin-cyclophosphamide proved to have a
significantly better therapeutic index than cisplatin- cyclophosphamide in
patients with stage III (suboptimal) and stage IV ovarian cancer.
This article has been cited by other articles:
|
|
|
|
 
R. P. Rocconi, T. O. Kirby, R. S. Seitz, R. Beck, J. M. Straughn Jr, R. D. Alvarez, and W. K. Huh
Lipoxygenase Pathway Receptor Expression in Ovarian Cancer
Reproductive Sciences,
March 1, 2008;
15(3):
321 - 326.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Markman
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer
Oncologist,
February 1, 2007;
12(2):
186 - 190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman and J. L. Walker
Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment
J. Clin. Oncol.,
February 20, 2006;
24(6):
988 - 994.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and A. du Bois
Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel
J. Clin. Oncol.,
February 1, 2006;
24(4):
579 - 586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Crawford, P. A. Vasey, J. Paul, A. Hay, J. A. Davis, and S. B. Kaye
Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial
J. Clin. Oncol.,
December 1, 2005;
23(34):
8802 - 8811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. du Bois, H.-J. Luck, W. Meier, H.-P. Adams, V. Mobus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schroder, et al.
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
J Natl Cancer Inst,
September 3, 2003;
95(17):
1320 - 1329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman
Role of Intraperitoneal Chemotherapy in the Front-Line Setting
J. Clin. Oncol.,
May 15, 2003;
21(90100):
145s - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Alberts
A Unifying Vision of Cancer Therapy for the 21st Century
J. Clin. Oncol.,
November 1, 1999;
17(90001):
13 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst,
October 6, 1999;
91(19):
1616 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Geisler, H. Bonnefoi, and M. E. Gore
Optimal Cytoreduction in Stage IV Ovarian Carcinoma
J. Clin. Oncol.,
September 1, 1999;
17(9):
3002 - 3002.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bonnefoi, R. P. A'Hern, C. Fisher, V. Macfarlane, D. Barton, P. Blake, J. H. Shepherd, and M. E. Gore
Natural History of Stage IV Epithelial Ovarian Cancer
J. Clin. Oncol.,
March 1, 1999;
17(3):
767 - 767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al.
Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer
J. Clin. Oncol.,
March 1, 1999;
17(3):
921 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Alberts and R. T. Dorr
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
Oncologist,
February 1, 1998;
3(1):
15 - 34.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Makatsoris and M. V. Seiden
High-Dose Therapy for Ovarian Carcinoma
Oncologist,
October 1, 1997;
2(5):
330 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med.,
November 18, 1993;
329(21):
1550 - 1559.
[Full Text]
|
|
|
|
